Guest-host Relationship of Cyclodextrin and its Pharmacological Benefits

被引:8
作者
Alshati, Fatmah [1 ]
Alahmed, Teejan Ameer Abed [2 ]
Sami, Farheen [3 ]
Ali, Md. Sajid [4 ]
Majeed, Shahnaz [5 ]
Murtuja, Sheikh [6 ]
Hasnain, M. Saquib [6 ]
Ansari, Mohammed Tahir [2 ,7 ]
机构
[1] Univ Nottingham, Sch Pharm, Univ Pk, Nottingham NG7 2RD, England
[2] Univ Nottingham Malaysia, Sch Pharm, Jalan Broga, Semenyih 43500, Selangor, Malaysia
[3] Hygia Inst Pharmaceut Sci & Res, Dept Pharmaceut, Lucknow, India
[4] Jazan Univ, Coll Pharm, Dept Pharmaceut, Jazan, Saudi Arabia
[5] Univ Kuala Lumpur, Royal Coll Med Perak, Dept Pharm, Ipoh, Malaysia
[6] Palamu Inst Pharm, Dept Pharm, Chianki 822102, Jharkhand, India
[7] Univ Nottingham Malaysia, Sch Pharm, Jalan Broga, Semenyih 43500, Selangor, Malaysia
关键词
Beta-cyclodextrin; anticancer drugs; PFASs; anti-tubercular drugs; solid dispersion; drug delivery; HYDROXYPROPYL-BETA-CYCLODEXTRIN; DRUG-DELIVERY SYSTEM; INCLUSION COMPLEXES; IN-VITRO; PHYSICOCHEMICAL PROPERTIES; MOLECULAR DOCKING; NANOPARTICLES; ANTIFUNGAL; CANCER; NANOCARRIERS;
D O I
10.2174/0113816128266398231027100119
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Many methods, including solid dispersion, micellization, and inclusion complexes, have been employed to increase the solubility of potent drugs. Beta-cyclodextrin (beta CD) is a cyclic oligosaccharide consisting of seven glucopyranoside molecules, and is a widely used polymer for formulating soluble inclusion complexes of hydrophobic drugs. The enzymatic activity of Glycosyltransferase or alpha-amylase converts starch or its derivatives into a mixture of cyclodextrins. The beta CD units are characterized by alpha-(1-4) glucopyranose bonds. Cyclodextrins possess certain properties that make them very distinctive because of their toroidal or truncated cage-like supramolecular configurations with multiple hydroxyl groups at each end. This allowed them to encapsulate hydrophobic compounds by forming inclusion complexes without losing their solubility in water. Chemical modifications and newer derivatives, such as methylated beta CD, more soluble hydroxyl propyl methyl beta CD, and sodium salts of sulfobutylether-beta CD, known as dexolve (R) or captisol (R), have envisaged the use of CDs in various pharmaceutical, medical, and cosmetic industries. The successful inclusion of drug complexes has demonstrated improved solubility, bioavailability, drug resistance reduction, targeting, and penetration across skin and brain tissues. This review encompasses the current applications of beta-CDs in improving the disease outcomes of antimicrobials and antifungals as well as anticancer and anti-tubercular drugs.
引用
收藏
页码:2853 / 2866
页数:14
相关论文
共 126 条
  • [1] Cyclodextrin Enhances Corneal Tolerability and Reduces Ocular Toxicity Caused by Diclofenac
    Abdelkader, Hamdy
    Fathalla, Zeinab
    Moharram, Hossam
    Ali, Taha F. S.
    Pierscionek, Barbara
    [J]. OXIDATIVE MEDICINE AND CELLULAR LONGEVITY, 2018, 2018
  • [2] Nanotechnological Advances in the Treatment of Epilepsy
    Ali, Ola Asem Mahmoud Abdou
    Shaikh, Mohd Farooq
    Hasnain, M. Saquib
    Sami, Farheen
    Khan, Abdullah
    Ansari, Mohammed Tahir
    [J]. CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS, 2022, 21 (10) : 994 - 1003
  • [3] Alizadeh Nina, 2021, Nova Biologica Reperta, V8, P84, DOI 10.29252/nbr.8.2.84
  • [4] Effect of β-cyclodextrin derivatives on the kinetics of degradation of cefotaxime sodium in solution state
    Alsarra, I. A.
    Ahmed, M. O.
    El-Badry, M.
    Alanazi, F. K.
    Al-Mohizea, A. M.
    Ahmed, S. M.
    [J]. JOURNAL OF DRUG DELIVERY SCIENCE AND TECHNOLOGY, 2007, 17 (05) : 353 - 357
  • [5] Development of Anacardic Acid/hydroxypropyl-β-cyclodextrin inclusion complex with enhanced solubility and antimicrobial activity
    Anjum, Md Meraj
    Patel, Krishna Kumar
    Pandey, Nidhi
    Tilak, Ragini
    Agrawal, Ashish Kumar
    Singh, Sanjay
    [J]. JOURNAL OF MOLECULAR LIQUIDS, 2019, 296
  • [6] Ansari M.T., 2018, Curr. Nanomed, V8, P225
  • [7] Ansari M.T., 2022, CHITOSAN DRUG DELIV, V2022, P389, DOI [10.1016/B978-0-12-819336-5.00002-9, DOI 10.1016/B978-0-12-819336-5.00002-9]
  • [8] Ansari M.T., 2017, Int. J. Pharma Bio Sci, V8, P21, DOI [10.22376/ijpbs.2017.8.4.p21-29, DOI 10.22376/IJPBS.2017.8.4.P21-29]
  • [9] Ansari M.T., 2017, Eur J Biomed Pharm Sci, V4, P586
  • [10] Lipid-based Nanocarriers for Cancer and Tumor Treatment
    Ansari, Mohammed Tahir
    Ramlan, Thiya Anissa
    Jamaluddin, Nurul Nadia Binti
    Zamri, Nurshahiera
    Salfi, Roshan
    Khan, Abdullah
    Sami, Farheen
    Majeed, Shahnaz
    Hasnain, M. Saquib
    [J]. CURRENT PHARMACEUTICAL DESIGN, 2020, 26 (34) : 4272 - 4276